To the Editor
Chronic spontaneous urticaria (CSU) is defined as recurrence of wheals, angioedema, or both for > 6 weeks due to known or unknown causes. According to current guidelines, non-sedative H1-antihistamines (nsAH) are the first-line therapy of CSU (1) . But even up-dosing to four times the standard dose can provide symptom control in only less than 50% of CSU patients (2) . Identification of biomarkers for predicting the response to nsAH is necessary for developing an individualized treatment. Total IgE, D-dimer, fibrinogen, ESR and C-reactive protein (CRP) have been previously investigated as potential biomarkers of CSU activity and/or response to treatment (3) (4) (5) . Herein, we for the first time evaluated their combination for predicting the outcome of treatment with levocetirizine in CSU patients. 31.13, U = 895, р = 0.019), higher serum levels of CRP (mean rank: 43.02 vs 31.94, U = 901, р = 0.031) and D-dimer (mean rank: 42.97 vs 30.95, U = 900.5, р = 0.019) than those with negative ASST. All patients were divided into two groups based on response to levocetirizine for discriminant analysis: responders (n = 42, 50%) and non-responders (n = 42, 50%). Levocetirizine was more often effective in patients with mild CSU compared to those with severe disease (66. 7 and co-workers where total IgE was suggested as a marker of severe CSU (7). Thus, the role of total IgE in CSU should be better characterized in further research. IgG-anti-IgE/FceRI autoantibodies play a role in a subpopulation of CSU patients (8) . We observed that positive ASST is associated with more severe disease, higher serum levels of CRP and D-dimer. Obtained results suggest that positive ASST is more often seen in non-responders. Thus, we found that the elevation of CRP, ESR, D-dimer and fibrinogen is associated with more active disease, low quality of life and lack of response to standard doses of levocetirizine. Evaluation of these markers may be considered before starting treatment with nsAH. Further research into the mechanisms behind elevation of these parameters in antihistamine-resistant CSU is required.
show Within-groups correlation matrix shows correlations between predictors (table 2) . There is a positive correlation between D-dimer, fibrinogen, CRP and ESR. As already mentioned, high levels of these are associated with lack of response to levocetirizine (table 1) . There is also a negative correlation between values of D-dimer and CU-Q2oL, CRP and CU-Q2oL, total IgE and UAS, CU-Q2oL and UAS. Only total IgE correlates positively with CU-Q2oL. Wilks' lambda is 0.620, (χ 2 = 37.471, p < 0.001) indicating a good discriminatory ability of the discriminant function to distribute cases into groups. The summary of number of subjects classified correctly and incorrectly for responders are 33 (78.6%) and 9 (21.4%), respectively. The summary of number of subjects classified correctly and incorrectly for non-responders are 34 (81%) and 8 (19.0%), respectively. The discriminant function worked equally well for each group of dependent variable. Overall, 79.8% of cases are correctly classified. To the best of our knowledge, we were the first to assess the set of biomarkers in the same group of CSU patients for predicting response to nsAH. The role of D-dimer and activation of coagulation in CSU pathogenesis is widely discussed (3) (4) (5) . Patients with high levels of D-dimer, fibrinogen and/or CRP are shown to have severe CSU (3, 5, 6 ) that is in the line with the results of our study. We reported elevation of total IgE serum levels in responders with mild CSU that is contradictory to the findings by Kessel 
Learning points
• CRP, ESR, D-dimer and fibrinogen seem to be useful markers for prediction of response to levocetirizine in CSU patients.
• Elevation of these markers is associated with more active disease, low quality of life, and a lack of response to standard doses of levocetirizine.
• Evaluation of these parameters may be considered before starting the treatment with non-sedative antihistamines, and provides additional justification for administration of high doses of antihistamines.
